Ophthalmic surgery, lasers & imaging retina · 2026
Demographic and Prevalence Dynamics of Macular Telangiectasia Type 2 From 2015 to 2024.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moir John T, Kim Sonia B, Allan Kevin C, Kaelber David C, Singh Rishi P, Talcott Katherine E
Аннотация
BACKGROUND AND OBJECTIVE: This study sought to provide a recent estimate for the prevalence of macular telangiectasia type 2 (MacTel) with respect to age, race/ethnicity, and sex.
PATIENTS AND METHODS: A cross-sectional study from 2015 to 2024 was performed for adults in the United States aged ≥ 35 years within an electronic health record data platform. Patients with MacTel were identified as those with a corresponding International Classification of Diseases 10th revision (ICD-10) diagnosis code. The prevalence of MacTel was calculated at each year of the study period and stratification was performed by age, race, ethnicity, and sex.
RESULTS: In 2024, the prevalence of MacTel was 9.06 patients per 100,000, representing a 1.91-fold increase from 2015 (95% CI 1.79-2.03). Over that same timespan, the ratio of increase in MacTel was greater than the ratio of increase of age-related macular degeneration (AMD) (odds ratio 1.25, 95% 1.17-1.33).
CONCLUSION: The prevalence of MacTel is lower than previously estimated but has been increasing at a striking rate from 2015 to 2024 that outpaces AMD.
PATIENTS AND METHODS: A cross-sectional study from 2015 to 2024 was performed for adults in the United States aged ≥ 35 years within an electronic health record data platform. Patients with MacTel were identified as those with a corresponding International Classification of Diseases 10th revision (ICD-10) diagnosis code. The prevalence of MacTel was calculated at each year of the study period and stratification was performed by age, race, ethnicity, and sex.
RESULTS: In 2024, the prevalence of MacTel was 9.06 patients per 100,000, representing a 1.91-fold increase from 2015 (95% CI 1.79-2.03). Over that same timespan, the ratio of increase in MacTel was greater than the ratio of increase of age-related macular degeneration (AMD) (odds ratio 1.25, 95% 1.17-1.33).
CONCLUSION: The prevalence of MacTel is lower than previously estimated but has been increasing at a striking rate from 2015 to 2024 that outpaces AMD.